We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





Ultrasensitive Troponin-I Assay to Be Introduced at the AACC Clinical Lab Expo

By LabMedica International staff writers
Posted on 01 Aug 2013
Print article
An advanced rapid assay for the heart attack biomarker troponin-I is being introduced to American cardiac researchers and clinicians at the AACC (American Association for Clinical Chemistry) Clinical Lab Expo in Houston (TX, USA), from July 30-August 1, 2013.

Abbot Diagnostics (Abbot Park, IL, USA) will be demonstrating the ARCHITECT High Sensitive Troponin-I (hsTnI) assay at the Clinical Lab Expo. In a study recently completed at Brigham and Women’s Hospital (Boston, MA, USA) this test was compared to a fourth generation troponin T assay among 4,695 patients presenting with severe chest pain.

Results revealed that the ARCHITECT hsTnI assay could detect very low levels of troponin-I, which allowed doctors to evaluate whether or not patients were having a heart attack within two to four hours after presentation. Furthermore, the test was so sensitive that doctors were able to predict which patients presenting with symptoms of a heart attack, such as severe chest pain, were at a higher risk for having a heart attack up to 30 days later.

"This study adds to the clinical evidence confirming the advantages of Abbott’s high sensitive troponin test to provide more insight to clinicians about which patients are at greater risk for a future heart attack as compared to contemporary tests," said Dr. John Frels, divisional vice president, diagnostics research at Abbott Diagnostics. "This is important information for patient care because it may help doctors focus on the patients at greater risk for appropriate management."

The ARCHITECT hsTnI assay – already being marketed in Europe – was designed to run on Abbott’s automated ARCHITECT family of analyzers.

Related Links:
Abbot Diagnostics


Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Pipet Controller
Stripettor Pro
New
Epstein-Barr Virus Test
Mononucleosis Rapid Test

Print article

Channels

Clinical Chemistry

view channel
Image: Professor Nicole Strittmatter (left) and first author Wei Chen stand in front of the mass spectrometer with a tissue sample (Photo courtesy of Robert Reich/TUM)

Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication

Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more

Molecular Diagnostics

view channel
Image: Health Canada has approved SPINEstat, a first-in-class diagnostic blood test for axSpA, as a Class II medical device (Photo courtesy of Augurex)

First-in-Class Diagnostic Blood Test Detects Axial Spondyloarthritis

Axial spondyloarthritis (axSpA) is a chronic inflammatory autoimmune condition that typically affects individuals during their most productive years, with symptoms often emerging before the age of 45.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.